Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A hepatitis C virus (HCV) vaccine comprising envelope glycoproteins gpE1/gpE2 derived from a single isolate elicits broad cross-genotype neutralizing antibodies in humans.
Law JL, Chen C, Wong J, Hockman D, Santer DM, Frey SE, Belshe RB, Wakita T, Bukh J, Jones CT, Rice CM, Abrignani S, Tyrrell DL, Houghton M. Law JL, et al. Among authors: hockman d. PLoS One. 2013;8(3):e59776. doi: 10.1371/journal.pone.0059776. Epub 2013 Mar 19. PLoS One. 2013. PMID: 23527266 Free PMC article.
Native Folding of a Recombinant gpE1/gpE2 Heterodimer Vaccine Antigen from a Precursor Protein Fused with Fc IgG.
Logan M, Law J, Wong JAJ, Hockman D, Landi A, Chen C, Crawford K, Kundu J, Baldwin L, Johnson J, Dahiya A, LaChance G, Marcotrigiano J, Law M, Foung S, Tyrrell L, Houghton M. Logan M, et al. Among authors: hockman d. J Virol. 2016 Dec 16;91(1):e01552-16. doi: 10.1128/JVI.01552-16. Print 2017 Jan 1. J Virol. 2016. PMID: 27795422 Free PMC article.
A Recombinant Hepatitis C Virus Genotype 1a E1/E2 Envelope Glycoprotein Vaccine Elicits Antibodies That Differentially Neutralize Closely Related 2a Strains through Interactions of the N-Terminal Hypervariable Region 1 of E2 with Scavenger Receptor B1.
Johnson J, Freedman H, Logan M, Wong JAJ, Hockman D, Chen C, He J, Beard MR, Eyre NS, Baumert TF, Tyrrell DL, Law JLM, Houghton M. Johnson J, et al. Among authors: hockman d. J Virol. 2019 Oct 29;93(22):e00810-19. doi: 10.1128/JVI.00810-19. Print 2019 Nov 15. J Virol. 2019. PMID: 31462563 Free PMC article.
Functional and immunogenic characterization of diverse HCV glycoprotein E2 variants.
Khera T, Behrendt P, Bankwitz D, Brown RJP, Todt D, Doepke M, Khan AG, Schulze K, Law J, Logan M, Hockman D, Wong JAJ, Dold L, Gonzalez-Motos V, Spengler U, Viejo-Borbolla A, Ströh LJ, Krey T, Tarr AW, Steinmann E, Manns MP, Klein F, Guzman CA, Marcotrigiano J, Houghton M, Pietschmann T. Khera T, et al. Among authors: hockman d. J Hepatol. 2019 Apr;70(4):593-602. doi: 10.1016/j.jhep.2018.11.003. Epub 2018 Nov 13. J Hepatol. 2019. PMID: 30439392
Effect of Different Adjuvants on the Longevity and Strength of Humoral and Cellular Immune Responses to the HCV Envelope Glycoproteins.
Akache B, Deschatelets L, Harrison BA, Dudani R, Stark FC, Jia Y, Landi A, Law JLM, Logan M, Hockman D, Kundu J, Tyrrell DL, Krishnan L, Houghton M, McCluskie MJ. Akache B, et al. Among authors: hockman d. Vaccines (Basel). 2019 Dec 3;7(4):204. doi: 10.3390/vaccines7040204. Vaccines (Basel). 2019. PMID: 31816920 Free PMC article.
SARS-COV-2 recombinant Receptor-Binding-Domain (RBD) induces neutralizing antibodies against variant strains of SARS-CoV-2 and SARS-CoV-1.
Law JLM, Logan M, Joyce MA, Landi A, Hockman D, Crawford K, Johnson J, LaChance G, Saffran HA, Shields J, Hobart E, Brassard R, Arutyunova E, Pabbaraju K, Croxen M, Tipples G, Lemieux MJ, Tyrrell DL, Houghton M. Law JLM, et al. Among authors: hockman d. Vaccine. 2021 Sep 24;39(40):5769-5779. doi: 10.1016/j.vaccine.2021.08.081. Epub 2021 Aug 26. Vaccine. 2021. PMID: 34481699 Free PMC article.
53 results